2026-08-29T10:11:04Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/270662025-12-18T12:57:40Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Davison, Beth A author Abbate, Antonio author Cotter, Gad author Pascual-Figal, Domingo author Van Tassell, Benjamin author Villota, Julio Núñez author Atabaeva, Lina author Freund, Yonathan author Aimo, Alberto author Biegus, Jan author Golino, Michele author Del Buono, Marco Giuseppe author Chioncel, Ovidiu author Cohen-Solal, Alain author Edwards, Christopher author Fernández-Villa, Noelia author Filippatos, Gerasimos author González-Juanatey, José Ramón author Hayrapetyan, Hamlet author Ibáñez, Borja author Iborra, Pau Llàcer author Moroni, Francesco author Ter Maaten, Jozine M author Markley, Roshanak author González-Martín, Javier author Martínez-Sellés, Manuel author Drambyan, Mayranush author Metra, Marco author Mirabet, Sonia author Mshetsyan, Andranik author Novosadova, Maria author Pagnesi, Matteo author Ponikowski, Piotr author Riquelme-Pérez, Alejandro author Sadoune, Malha author Sánchez, Manuel Anguita author Simon, Tabassome author Taibo-Urquía, Mikel author Takagi, Koji author Villar, Sandra author Liu, Chao author Voors, Adriaan A author Mebazaa, Alexandre author Mann, Douglas L author Bayés-Genís, Antoni author 2025-05 We examined current evidence regarding the effects of anti-inflammatory therapies in patients with acute heart failure (AHF) on the risk of cardiovascular outcomes, inflammatory markers, natriuretic peptides, and renal function. Despite growing evidence that inflammation plays a pivotal role in both the development and progression of heart failure, including AHF, only a few trials have been conducted to date in patients with AHF. A systematic literature search of PubMed, Medline, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov was conducted in November 2024 to identify randomized controlled trials (RCTs) evaluating anti-inflammatory therapies in adult patients with AHF. Meta-analyses were conducted to estimate effects on clinical outcomes (death, HF readmission, or worsening HF) and inflammatory and other markers. Five RCTs were identified that enrolled a total of 289 patients to an anti-inflammatory intervention and 273 to a control. Prednisone was examined in two RCTs, anakinra in two, and colchicine in one. Three of the five trials required elevated C-reactive protein (CRP) level for entry. Anti-inflammatory therapy was associated with a reduced risk of the composite outcome (hazard ratio 0.55 [95% CI 0.35-0.86]) and an overall 54% greater reduction in CRP to end of therapy (ratio of geometric mean ratios 0.46 [95% CI 0.29-0.73]), which varied across studies. NT-proBNP and creatinine were not significantly affected. The analysis is limited by the small number of studies but suggests that anti-inflammatory therapy reduces inflammation and may reduce the risk of adverse clinical outcomes in patients with AHF. Heart Fail Rev. 2025 May;30(3):575-587. HEART FAILURE REVIEWS 39939545 https://hdl.handle.net/20.500.12105/27066 Acute heart failure Anti-inflammatory agents Inflammation Prognosis Effects of anti-inflammatory therapy in acute heart failure: a systematic review and meta-analysis.